You are here: Industry Insights > GSK

News List

GSK to buy-out Novartis’ stake in consumer health JV pharmatimes
July 20, 2018
GlaxoSmithKline is buying Novartis’ stake in the firms’ consumer healthcare unit, the announcement coming just days after the drug giant said it would not pursue acquisition of Pfizer’s consumer healthcare business.
GSK and Kymera team up for protein degradation alliance pharmatimes
July 18, 2018
GlaxoSmithKline and Kymera have sealed a pact to work together on the discovery of new medicines based on protein degradation.
GSK hands rare disease gene therapies over to Orchard pharmatimes
July 17, 2018
Orchard Therapeutics has snapped up GlaxoSmithKline’s portfolio of approved and investigational rare disease gene therapies.
GSK picks Kevin Sim to lead business development for pharma R&D pharmatimes
July 17, 2018
GlaxoSmithKline has named Kevin Sim as senior vice president and head of worldwide business development for pharmaceuticals R&D.
GSK confirms £250m deal to sell experimental drug to Dermavent Sciences pharmafile
July 17, 2018
British company GlaxoSmithKline has announced that it will sell the rights to its experimental dermatology drug, tapinarof, to Roivant Sciences’ subsidiary Dermavent Sciences, in a deal worth up to £250 million.
GSK picks Kevin Sim to lead business development for pharma R&D pharmatimes
July 16, 2018
GlaxoSmithKline has named Kevin Sim as senior vice president and head of worldwide business development for pharmaceuticals R&D.
GSK sells psoriasis/dermatitis therapy to Dermavant pharmatimes
July 16, 2018
Tapinarof is an investigational therapeutic aryl hydrocarbon receptor modulating agent (TAMA) which has been evaluated as a topical therapy in multiple Phase I and Phase II studies involving over 800 human subjects.
GSK/Innoviva’s Trelegy Ellipta wins expanded nod for COPD pharmatimes
July 13, 2018
US regulators have approved GlaxoSmithKline and Innoviva’s Trelegy Ellipta to treat a wider population of chronic obstructive pulmonary disease (COPD) patients.
GSK reports Q1 sales decline pharmatimes
July 13, 2018
GlaxoSmithKline has booked a 2 percent dip in revenues for the first quarter to £7.2 billion, after results were hit by a “significant currency impact” and lower sales of prescription drugs.
GSK sells psoriasis/dermatitis therapy to Dermavant pharmatimes
July 13, 2018
GlaxoSmithKline has sold rights to an experimental therapy with potential in psoriasis and dermatitis to Dermavant in a deal worth $330 million.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 40 41 Next page